Navigation Links
Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
Date:1/10/2012

arge number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding Omeros' expectation regarding its ability unlock orphan GPCRs and add a large number of new drug targets and their corresponding compounds to the market; the disorders that could potentially be treated by drugs that target unlocked orphan receptors, including GPR25, GPR32, GPR80, GPR135 and MAS1; Omeros' ability to obtain broad patent protection for the orphan GPCRs that it has unlocked; the pharmaceutical industry's ability to design proprietary compounds that interact with these receptors; and the Company's ability to complete the screening of all Class A orphans by the end of 2012. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
2. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
3. Omeros to Present at Two Upcoming Conferences
4. Omeros to Present at Future Leaders in the Biotech Industry Conference
5. Omeros to Present at Needham Healthcare Conference
6. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
7. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
8. Omeros Secures $40 Million Committed Equity Financing Facility
9. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
10. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
11. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Yuma Regional Cancer Center Officially Opens ... comprehensive cancer care to Yuma, Arizona. , The ... has officially opened. A Mayo Clinic Care Network ... as open, semi-private and private infusion rooms, oncology ... Center, hematology, rehabilitation center, a pain management program ...
(Date:7/30/2014)... 30, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... and proprietary technologies are used to discover, develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... Dubinski as Vice President and Chief Financial Officer. ... and information technology operations for Dyadic and will ...
(Date:7/30/2014)... , July 30, 2014   Epic Sciences, ... and develops novel diagnostics to personalize and advance the ... of Gregory T. Lucier as chairman of ... and CEO of Life Technologies (formerly Invitrogen). Mr. Lucier ... Epic commercializes its circulating rare cell analysis platform with ...
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... SAN DIEGO , June 2 Neurocrine Biosciences, Inc. (Nasdaq: ... Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2010 Global ... in New York . , ... The live presentation for the Jefferies conference takes place on Wednesday, June ...
... International ... ... 2010 -- The International Food Information Council (IFIC) 2010 “ Consumer Perceptions of Food ... consider its potential benefits for reducing the impact of food and food production on ...
... Repligen Corporation (Nasdaq: RGEN ) announced today that it will ... Wednesday, June 9th, 2010 , before the market opens.  The Company President ... conference call and webcast on the same day at 10:00 a.m. EDT ... Company. , , , ...
Cached Biology Technology:Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference 2Interest in Environment & Sustainability Prevails in Food Technology Survey 2Interest in Environment & Sustainability Prevails in Food Technology Survey 3Interest in Environment & Sustainability Prevails in Food Technology Survey 4Interest in Environment & Sustainability Prevails in Food Technology Survey 5Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 3
(Date:7/30/2014)... York University is paving the way for a ... and military troops exposed to poisonous chemicalsparticularly those ... article in the current issue of the journal ... organophosphates, which are compounds commonly used in pesticides ... by NYU School of Engineering Associate Professor of ...
(Date:7/30/2014)... A deep-sea octopus protected and tended her eggs until ... published July 30, 2014 in the open-access journal ... Aquarium Research Institute and colleagues. , Octopuses typically have ... females protect and take care of their fertilized eggs ... eggs for 1 to 3 months, but little is ...
(Date:7/30/2014)... Everybody knows the shortest distance between two points is ... that sperm have been taking the familiar axiom to ... usually thought to be intense, with each racing for ... in some species, sperm form cooperative groups that allow ... , A new study, conducted by Heidi Fisher, ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Deep-sea octopus has longest-known egg-brooding period 2When cooperation counts 2When cooperation counts 3
... Researchers from Michigan State University,s departments of Electrical ... new wearable sensor network to assess a person,s physical ... engineering professor Subir Biswas, participants will wear three small, ... lower leg that during any physical activity will ...
... Research (SFBR) in San Antonio have found a gene ... in the blood as a result of a high-cholesterol ... developed at SFBR that has normal blood levels of ... low-cholesterol diet, but extremely elevated levels of LDL cholesterol ...
... Animal flocks, be it honeybees, fish, ants or birds, ... decisions at a moment,s notice, a phenomenon which has ... today, Wednesday 15 September, in New Journal of ... German Physical Society), uses a particle model to explain ...
Cached Biology News:Wearable sensor technology to measure physical activity 2Scientists find gene for high cholesterol in blood 2Understanding behavioral patterns: Why bird flocks move in unison 2
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... This reagent has been developed ... for the reduction of nonspecific background ... Traditional methods describe blocking peroxidase with ... hydrogen peroxide in combination with additional ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Biology Products: